Status:
RECRUITING
The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration
Lead Sponsor:
Nantes University Hospital
Conditions:
Frontotemporal Lobar Degeneration
Eligibility:
All Genders
50-75 years
Phase:
NA
Brief Summary
Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and/or language. From a pathological standpoint, like the great major...
Detailed Description
Participant with Frontotemporal Lobar degeneration equally distributed into behavioral variant of frontotemporal dementia (bvFTD), language variant with primary progressive aphasia (PPA) and motor pre...
Eligibility Criteria
Inclusion
- Inclusion Criteria (patients):
- Adressed or followed at memory clinic or ALS expert center at Nantes university hospital.
- Aged 50-75 years
- Fulfilling current diagnosis criteria for one of the disorder: vcfFTD, non-Alzheimer PPA (semantic or non fluent), DCB or PSP,ALS
- MMSE ≥ 18
- Membership of social security scheme
- Inclusion Criteria (healthy volunteers):
- No history of neurological disease, diabetes, or alteration/damage of peripheral nervous system
- Aged 50-75 years Paired to at least one patient on age (less or more 5 years)
- MOCA ≥ 26
- Membership of social security scheme
- Non inclusion Criteria (Patients and healthy volunteers):
- Concomitting conditions affecting the peripheral nervous system such as but not limited to diabetes, renal failure, thyroid disorder, vitamin B12 deficiency, acute and chronic inflammatory diseases HIV, syphilis
- Know allergy to local anesthetic
- Known coagulopathy
- Pregnant women or breastfeeding women
- Person under court protection sous sauvegarde de justice
- Person under guardianship
- Inability to sign an informed consent
- Non inclusion criteria (Patients) • Patient with neurological disease other than FTLD
- Non inclusion criteria (Healthy volunteers) :
- • Evidence of neurological disorder at the inclusion including but not limted to FTLD, Parkinson disease, Alzheimer disease, lewy body dementia, Huntington disease, systemic lupus erythematosus multiple sclerosis; learning disabilities, mental retardation, severe hypoxic brain injuries, brain trauma with permanent cognitive impairments.
Exclusion
Key Trial Info
Start Date :
December 17 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06490822
Start Date
December 17 2024
End Date
July 1 2027
Last Update
December 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France, 44093